GSK Selects Exelixis’ Phase II MET Inhibitor XL880
This article was originally published in The Pink Sheet Daily
Executive Summary
XL880 is first compound to be selected by GSK under collaboration that allows U.K. drug maker to choose three of 12 Exelixis candidates.